Answer
Tecartus (brexucabtagene autoleucel) is indicated for adults with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.
Sources for this answer
- TecartusGilead Sciences Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 16Document updated
Sources checked